Depo-Provera Mass Tort Update: July 2026

For a drug that has been prescribed to millions of women over the past three decades, Depo-Provera has had an unusually controversial history.

Long before the current wave of lawsuits, the injectable contraceptive faced repeated regulatory hurdles in the United States. The U.S. Food and Drug Administration (FDA) declined multiple applications to approve Depo-Provera as a contraceptive before ultimately approving it in 1992, following years of debate over its long-term safety, study quality, and potential cancer-related risks.

More than thirty years later, the drug is once again at the center of a growing legal battle. Beginning in 2024, thousands of women across the United States began filing lawsuits alleging that long-term use of Depo-Provera caused them to develop intracranial meningiomas, which are non-cancerous tumors that form in the membranes surrounding the brain and spinal cord.

Although these tumors are often classified as benign, they can produce devastating consequences, including seizures, vision loss, memory impairment, strokes, permanent neurological deficits, and the need for complex brain surgery.

The lawsuits allege that the manufacturers failed to adequately warn physicians and patients despite mounting scientific evidence linking prolonged exposure to an increased risk of meningioma.

The litigation is still in its early stages, but it is moving quickly. Recent scientific studies, ongoing federal court proceedings, and growing numbers of filed claims have transformed what began as isolated lawsuits into one of the most closely watched pharmaceutical mass torts currently developing in the United States.

Why Are Women Filing Depo-Provera Lawsuits?

Our defective drug and medical equipment lawyers here at Van Law Firm find the Depo-Provera lawsuits unique because they don’t arise from a product recall, but rather new research and an evolving body of scientific evidence that has renewed longstanding concerns about the drug’s safety profile.

After decades of questions over the drug’s long-term safety profile, recent research strengthened evidence of a possible association between prolonged Depo-Provera use and intracranial meningiomas.

The turning point came in 2024, when a large French national case-control study published in The BMJ reported that women who used injectable medroxyprogesterone acetate, which is the active ingredient in Depo-Provera, for one year or longer had an approximately 5.5-fold increased risk of developing intracranial meningiomas requiring surgery. The findings drew international attention and reignited questions that had surfaced periodically during the drug’s regulatory history.

Since then, additional studies have continued to examine the relationship between prolonged exposure to progestin-based contraceptives and meningioma development. Although researchers continue to investigate the precise biological mechanisms involved, the growing body of evidence has prompted increased regulatory scrutiny in several countries and provided much of the scientific foundation for the current wave of litigation.

Allegations of Failure to Warn

The lawsuits generally allege two related propositions: first, that prolonged use of Depo-Provera increased the risk of developing intracranial meningiomas in certain patients, and second, that Pfizer failed to adequately warn physicians and patients about that risk despite emerging scientific evidence.

The second allegation forms the foundation of most of the litigation. Plaintiffs contend that the manufacturer knew, or should have known, that long-term exposure carried a greater risk than reflected in the drug’s labeling, yet failed to provide timely and adequate warnings that would have allowed physicians and patients to make more informed treatment decisions.

From a legal perspective, the central issue is not whether every Depo-Provera user will develop a brain tumor. Instead, the courts will be asked to determine whether:

• The potential risk was reasonably knowable
• The manufacturer’s warnings were legally sufficient in light of the available evidence
• Stronger or earlier warnings could have prevented some of the injuries now alleged by plaintiffs.

Those questions are expected to become increasingly important as discovery progresses. Internal company documents, post-market safety analyses, communications with regulators, and expert testimony will likely play a central role in determining what the manufacturer knew, when it knew it, and whether its response satisfied its legal duty to warn.

For a free legal consultation, call (725) 900-9000

Status of the Depo-Provera Lawsuits (June 2026)

What began as a handful of individual product liability lawsuits has rapidly developed into one of the largest pharmaceutical mass torts currently pending in the United States.

In addition to the fact that Depo-Provera is used by millions of women annually in the U.S., this is a drug that’s administered to primarily healthy women. Thus, the risk-benefit profile expected of such a drug (and per FDA regulations) are very strict.

Over the past two years, the litigation has progressed from a few complaints to fully coordinated federal proceedings involving thousands of plaintiffs, significant pretrial rulings, and a recently proposed global settlement framework.

Depo-Provera Lawsuits: A Timeline of the Major Developments

March 2024 – Landmark study reignites safety concerns

The publication of a large French national study in The BMJ marked the catalyst for the current litigation. Researchers reported that women who used injectable medroxyprogesterone acetate for one year or longer had an approximately 5.5-fold increased risk of intracranial meningiomas requiring surgery. The study attracted international attention and prompted attorneys across the United States to begin investigating potential product liability claims.

Mid to Late 2024 – The first lawsuits are filed

Following publication of the study, women diagnosed with intracranial meningiomas after prolonged Depo-Provera use began filing lawsuits against Pfizer and related defendants. Although each plaintiff’s medical history differed, the complaints generally alleged that the manufacturer failed to adequately warn physicians and patients about the potential risk of developing meningiomas after long-term use.

February 7, 2025 – Federal MDL established

As filings accelerated across multiple jurisdictions, the Judicial Panel on Multidistrict Litigation created MDL No. 3140, transferring federal Depo-Provera cases to the United States District Court for the Northern District of Florida before judge M. Casey Rodgers. The creation of the MDL allowed common issues, such as scientific evidence, expert testimony, and discovery, to be handled in a single coordinated proceeding while preserving each plaintiff’s individual claim.

Spring 2025 through Early 2026 – Discovery and case management

Throughout the following year, the court entered numerous case management and pretrial orders establishing procedures for document discovery, expert disclosures, proof-of-use requirements, pilot case selection, and leadership appointments. Much of the litigation shifted toward obtaining internal corporate documents, adverse event data, regulatory communications, and scientific evidence that may clarify what the manufacturers knew about the alleged risk and when they became aware of it.

June 2026 – Litigation reaches a major milestone

The most significant development to date occurred in June 2026, when the parties informed the court that they had reached a global settlement in principle for eligible plaintiffs participating in the federal MDL. In response, Judge Rodgers vacated the scheduled bellwether trial deadlines while settlement details continue to be negotiated.

Note that this is not a finalized settlement. Neither the financial terms nor the eligibility criteria have been made public, and the agreement does not automatically resolve every pending federal or state court case.

What Does the MDL Mean for Plaintiffs?

Despite the MDL, you should understand that the Depo-Provera litigation is not yet a class action. An MDL is designed to improve efficiency by coordinating pretrial proceedings for cases that share common factual questions. Each plaintiff retains an individual lawsuit, and any compensation is determined based on that person’s diagnosis, medical history, duration of Depo-Provera use, treatment, and resulting injuries.

From a practical standpoint, the MDL allows both sides to avoid duplicating discovery thousands of times while ensuring that common scientific issues are decided consistently.

What Happens Next?

Although the proposed settlement for the Depo-Provera lawsuits has changed the trajectory of the federal litigation, the process is far from complete. Among the issues still expected to shape the litigation are:

• Finalization of the proposed settlement program and eligibility criteria.
• Resolution of outstanding pretrial motions, including issues involving causation and federal preemption.
• Continued filing and evaluation of new claims.
• Ongoing state court proceedings, which remain separate from the federal MDL.
• Court approval and implementation of any finalized settlement structure.

For current and prospective plaintiffs, the most important takeaway is that the litigation remains active. Women who believe they developed an intracranial meningioma after prolonged Depo-Provera use should not assume that it is too late to explore their legal options simply because a settlement in principle has been announced. State filing deadlines continue to apply, and whether a future claim may qualify under any eventual settlement program will depend on the specific facts of the case.

Could You Be Eligible to File a Depo-Provera Lawsuit?

Not every woman who used Depo-Provera will have a legal claim. In general, the lawsuits involve individuals who received Depo-Provera injections over an extended period and were later diagnosed with an intracranial meningioma. Because these tumors often grow slowly, many women did not realize anything was wrong until years after beginning treatment.

Symptoms vary depending on the size and location of the tumor, but many plaintiffs describe experiencing persistent headaches, vision changes, dizziness, hearing problems, memory or cognitive difficulties, seizures, or weakness affecting one side of the body. In many cases, these symptoms ultimately led to brain imaging that revealed a meningioma, followed by surgery, radiation therapy, or ongoing neurological treatment.

While every case is unique, several factors tend to strengthen a potential claim:

• Long-term use of Depo-Provera, particularly for one year or longer.
• A confirmed diagnosis of an intracranial meningioma or brain tumor.
• Medical records documenting treatment, imaging, or surgery.
• Significant physical, neurological, or financial consequences resulting from the diagnosis.

Even if you’re unsure whether your situation meets these criteria, it may still be worth speaking with an attorney. Product liability cases are highly fact-specific, and an experienced lawyer can review your medical history, explain how current litigation may apply to your circumstances, and determine whether additional investigation is warranted.

Speak With a Defective Drug Lawyer

If you or a loved one developed an intracranial meningioma after using Depo-Provera, talking with an experienced defective drugs lawyer who has dealt with similar cases can help you understand your legal rights and how to seek justice. As the Depo-Provera lawsuits continue to evolve, having expert guidance in collecting and preserving medical records and starting the claims process early may help protect your ability to seek compensation.

The experienced attorneys at Van Law Firm have extensive experience in representing those who have been harmed by dangerous drugs and defective medical products in Nevada and Washington. If you believe your diagnosis may be linked to Depo-Provera, contact the firm for a free, no-obligation consultation.